REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 7th, 2019 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Agreement is made pursuant to the Stock Purchase Agreement, dated as of October 3, 2018, between the Company and the Purchaser (the “Purchase Agreement”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 7th, 2019 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of October 3, 2018, (the “Effective Date”) by and between Johnson & Johnson Innovation-JJDC, Inc. (the “Investor”), a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901, and Arrowhead Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, with its principal place of business at 225 S. Lake Avenue, Suite 1050, Pasadena, California 91101.
Research COLLABORATION AND Option AGREEMENTResearch Collaboration and Option Agreement • February 7th, 2019 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Option Agreement (“Agreement”), made as of the date of execution by the last Party to sign below (the “Execution Date”) and effective as of the Effective Date as defined below, is by and between Arrowhead Pharmaceuticals, Inc., a Delaware corporation with a place of business at 225 South Lake Avenue, Suite 1050, Pasadena, California 91101, USA (“Arrowhead”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation with a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (“Janssen”). Arrowhead and Janssen are at times referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • February 7th, 2019 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This License Agreement (“Agreement”), made as of the date of execution by the last Party to sign below (the “Execution Date”) and effective as of the Effective Date as defined below, is by and between Arrowhead Pharmaceuticals, Inc., a Delaware corporation with a place of business at 225 South Lake Avenue, Suite 1050, Pasadena, California 91101, USA (“Arrowhead”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation with a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (“Janssen”). Arrowhead and Janssen are at times referred to herein individually as a “Party” and collectively as the “Parties”.
